Thoroughbred Financial Services’s Cidara Therapeutics CDTX Stock Holding History

Thoroughbred Financial Services’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,602	Closed	-$1.24M	–	580
2025 Q4	$1.24M	Buy	5,602 +670	+14%	+$108K	0.07%	242
2025 Q3	$472K	Buy	+4,932	New	+$315K	0.03%	392

Thoroughbred Financial Services's CDTX Position: Q1 2026 in Review

Thoroughbred Financial Services sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 5,602 shares — an estimated $1.24M sold.

Thoroughbred Financial Services first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $1.24M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Thoroughbred Financial Services reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Thoroughbred Financial Services sold 5,602 Cidara Therapeutics shares in Q1 2026, an estimated $1.24M.
Thoroughbred Financial Services first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
Thoroughbred Financial Services's Cidara Therapeutics position peaked at $1.24M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Thoroughbred Financial Services's 13F filing for Q1 2026, filed 12 May 2026.